I’ve already talked with science writer Ed Yong about the new Nature iPS cell paper Araki, et al. (you can read Ed’s well-written piece here and you can another one on it by another one of my favorite writers, Monya Baker here), which suggests that iPS cells don’t trigger much in the way of an immune […]
Some thoughts on the Araki Nature iPS cell paper: an advance, but a few key caveats Read More »
Every year I make predictions about what the following year will bring us in the stem cell field. For example, last year I made some predictions for 2012 and I shortly will do a post on my predictions for 2013. First, how did I do with my predictions for this year, which I made in
Supposedly there is a type of normal adult stem cell that intrinsically possesses many of the same properties as embryonic stem cells (ESCs). No reprogramming needed. No blastocysts needed. These reportedly amazing cells, called Very Small Embryonic-Like Stem Cells (VSELs), can in theory be isolated from umbilical cord blood (UCB) or even bone marrow. Yet
It seems like just yesterday I was blogging about how concerned I was that iPS cells might be used in early phase human clinical trials as early as next year and that would be high risk given safety concerns about iPS cells. Oh, it was yesterday. Now today….. Yomiuri Shimbun, one of the top newspapers
The iPS cell field has had a relatively quiet 2012 so far, but one recent paper has drawn particular attention in the last 10 days. I’m talking about the paper from Jaenisch’s lab on iPS cells in Cell. Quite a few people are excited, but also scratching their heads a bit as to what this
Jaenisch’s new, complicated iPS paper in Cell: what the heck does it all mean? Read More »
What are the most important iPS cell papers so far? 1) Yamanaka’s first paper on mouse iPS cells. Revolutionary. Intriguing perspectives presented in day 1 of the iPS cell field. Interesting statements such as Myc is required. Also take a look at those other reprogramming factors that he tested…there’s a tremendous amount there, largely unexamined.
What are the best iPS cell papers so far? Read More »
The leading cause of death in America and many other countries of the world is cardiovascular disease (CVD) including heart attacks and strokes. In fact, CVD kills and disables more people than most often top killers combined including cancer. The myth that CVD is a “man’s disease” only makes the situation worse as in reality CVD
Transdifferentiation meets gene therapy to tackle heart disease Read More »
Each year at this time I start thinking about what the next year will bring for the stem cell field and make predictions. This year is no different and I’ve been pondering what 2012 has in store for us. You can read my predictions for 2011 here and see how I fared. Not too bad, but overly optimistic
Stem cell predictions for 2012: Science, CIRM, ACT, trends Read More »
I know you care about stem cells and research, but do you know much about epigenetics? You should. If you do not understand epigenetics then you do not understand stem cells. Don’t be put off by the complicated sounding name “epigenetics”. It’s really simple conceptually and below is your easy-to-understand guide. Epigenetics controls nearly every
A layman’s guide to stem cell epigenetics Read More »
Periodically we do updates on the iPS cell field and now seems like a good time. Where do things stand? Here’s my top 5 list of action items for the iPS cell field in the coming year. 5.) Methods on the brain. A significant fraction, some would argue too high a fraction, of iPS cell papers
Top 5 iPS cell action items Read More »